Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) will report first quarter 2026 financial results on Thursday, May 14, 2026 and hold a conference call at 8:30 a.m. Eastern Time. The call includes a Q&A and will be accessible by phone (Conf. ID 13760399) and live webcast.

Dial-in numbers and the webcast link are provided for investor access.

Market Context

This announcement sets the schedule and access details for Pelthos’s Q1 2026 results on May 14, 2026...

Analysis

This announcement sets the schedule and access details for Pelthos’s Q1 2026 results on May 14, 2026 at 8:30 a.m. ET, continuing its established practice of pre-announcing earnings dates. In the past, similar earnings-date news led to only a small -0.3% move. With an effective $200,000,000 shelf registration and recent commercial and clinical updates, investors may focus on upcoming revenue trends, cash position, and any capital-raising disclosures during the call.

Key Figures

Earnings date: May 14, 2026 Conference call time: 8:30 a.m. Eastern Time Toll-free dial-in: 1-877-451-6152 +2 more

5 metrics

Earnings date May 14, 2026 Scheduled Q1 2026 financial results release

Conference call time 8:30 a.m. Eastern Time Q1 2026 results conference call start

Toll-free dial-in 1-877-451-6152 U.S. access number for earnings call

International dial-in 1-201-389-0879 International access number for earnings call

Conference ID 13760399 Identifier for Q1 2026 earnings call

Previous Earnings date Reports

1 past event · Latest: Mar 09 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 09	Earnings date announcement	Neutral	-0.3%	Company scheduled Q4 and full-year 2025 results with an earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date news for PTHS saw a small negative move of -0.3%, indicating historically muted reactions to scheduling announcements.

Recent Company History

Recent news for PTHS has combined commercial and clinical execution with capital markets activity. An earlier earnings date release on Mar 19, 2026 was followed by Q4 2025 results showing ZELSUVMI revenue growth and financing actions. Additional updates covered a Phase 1b/2a trial initiation, a CFO transition, and investor conference participation. Today’s announcement continues the pattern of pre-announcing financial results with a scheduled conference call.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to hold a conference call at 8:30 a.m. ET

DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time.

Details for the conference call can be found below:

Date:	Thursday, May 14, 2026
Time:	8:30 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf. ID:	13760399

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When will Pelthos Therapeutics (PTHS) release Q1 2026 results?

Pelthos will release its Q1 2026 financial results on Thursday, May 14, 2026. According to Pelthos, the company will discuss results during a live conference call at 8:30 a.m. Eastern Time and provide a webcast link for remote listeners.

How can investors join the Pelthos (PTHS) May 14, 2026 conference call?

Investors can join via toll-free dial-in 1-877-451-6152 or international 1-201-389-0879. According to Pelthos, use Conference ID 13760399 and the company will host a live Q&A after the prepared remarks.

Where can I find the Pelthos (PTHS) webcast for the May 14, 2026 call?

The live webcast will be available at the provided web link for the May 14, 2026 call. According to Pelthos, the webcast URL is accessible for investors to listen to the prepared remarks and the Q&A session.

What time is the Pelthos (PTHS) conference call on May 14, 2026 in Eastern Time?

The Pelthos conference call is scheduled for 8:30 a.m. Eastern Time on May 14, 2026. According to Pelthos, the event will include financial remarks followed by a question-and-answer period for investors and analysts.

Will Pelthos (PTHS) provide a Q&A during the May 14, 2026 earnings call?

Yes, the May 14, 2026 call includes a question-and-answer period after the prepared remarks. According to Pelthos, participants on the live dial-in and webcast will be able to submit questions during the Q&A portion.